ACIPIMOX

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H6N2O3
Molecular Weight	154.1234
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=[N+]([O-])C=C(N=C1)C(O)=O

InChI

InChIKey=DJQOOSBJCLSSEY-UHFFFAOYSA-N

InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)

HIDE SMILES / InChI

Molecular Formula	C6H6N2O3
Molecular Weight	154.1234
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7438693 | https://www.ncbi.nlm.nih.gov/pubmed/8720602 | https://www.medicines.org.uk/emc/medicine/5355 | https://www.ncbi.nlm.nih.gov/pubmed/12522134 | https://www.ncbi.nlm.nih.gov/pubmed/12646212

Acipimox (5-methylpyrazinecarboxylic acid 4-oxide) is a new lipolysis inhibitor that has a distant chemical relationship with nicotinic acid (NA). The anti-lipolytic action of acipimox is mediated through suppression of intracellular cyclic AMP levels, with the subsequent decrease in cyclic AMP-dependent protein kinase activity, leading to the reduced association of hormone-sensitive lipase with triacylglycerol substrate in the lipid droplet of adipocytes. Acipimox has been identified as an agonist at G-protein coupled nicotinic acid HM74A and HM74B receptors. Acipimox (Olbetam) is indicated for the treatment as alternative or adjunct treatment to reduce triglyceride levels in patients who have not responded adequately to other treatments such as statin or fibrate treatment for hypertriglyceridaemia (Fredrickson type IV hyperlipoproteinaemia) and hypercholesterolaemia and hypertriglyceridaemia (Fredrickson type IIb hyperlipoproteinaemia).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Hydroxycarboxylic acid receptor 2 28 Target ID: CHEMBL3785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12522134	Agonist 2752	6.0 µM [EC50]
lipid catabolic process 1 Target ID: GO:0016042 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7438693 \| https://www.ncbi.nlm.nih.gov/pubmed/8720602	Inhibitor 8504
HM74 nicotinic acid GPCR 20 Target ID: CHEMBL4421 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12646212	Agonist 2752	4.39 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipoproteinemia type IV 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1914867 http://adisinsight.springer.com/drugs/800050700	Primary		Approved 8583	OLBETAM Approved Use Olbetam is indicated as alternative or adjunct treatment to reduce triglyceride levels in patients who have not responded adequately to other treatments such as statin or fibrate treatment for: • hypertriglyceridaemia (Fredrickson type IV hyperlipoproteinaemia); • hypercholesterolaemia and hypertriglyceridaemia (Fredrickson type IIb hyperlipoproteinaemia). Olbetam should be used after other measures have been taken such as dietary changes and other non-pharmacological treatment (e.g. exercise, weight reduction). It has not been shown that treatment of hyperlipoproteinaemia with acipimox leads to a reduction of cardiac morbidity or mortality.
Hyperlipoproteinemia type IIb 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1914867 http://adisinsight.springer.com/drugs/800050700	Primary		Approved 8583	OLBETAM Approved Use Olbetam is indicated as alternative or adjunct treatment to reduce triglyceride levels in patients who have not responded adequately to other treatments such as statin or fibrate treatment for: • hypertriglyceridaemia (Fredrickson type IV hyperlipoproteinaemia); • hypercholesterolaemia and hypertriglyceridaemia (Fredrickson type IIb hyperlipoproteinaemia). Olbetam should be used after other measures have been taken such as dietary changes and other non-pharmacological treatment (e.g. exercise, weight reduction). It has not been shown that treatment of hyperlipoproteinaemia with acipimox leads to a reduction of cardiac morbidity or mortality.

C_max

Value	Dose	Analyte	Population
3.51 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.03 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.68 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.31 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.858 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23447078/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
12.84 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.66 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.07 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.32 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.77 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13.345 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23447078/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.406 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.467 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.236 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.487 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.468 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.348 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19798634/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23447078/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	ACIPIMOX plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
1200 mg 3 times / day multiple, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3279968/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3279968/	Other AEs: Flushing, Itching... Other AEs: Flushing Itching Sources: https://pubmed.ncbi.nlm.nih.gov/3279968/
1200 mg single, oral Highest studied dose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7028536/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/7028536/	Sources: https://pubmed.ncbi.nlm.nih.gov/7028536/

AEs

AE	Significance	Dose	Population
Flushing		1200 mg 3 times / day multiple, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3279968/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3279968/
Itching		1200 mg 3 times / day multiple, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3279968/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3279968/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP4 290 BSEP 550 MRP2 499 MRP3 246 CYP19A1 429	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM0NTcxNCJ9fQ==	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM0NTcxNCJ9fQ==	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM0NTcxNCJ9fQ==	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDM0NTcxNCJ9fQ==	no [IC50 >133 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5310993#section=BioAssay-Results Page: 80.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5310993#section=BioAssay-Results Page: 104.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5310993#section=BioAssay-Results Page: 105.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5310993#section=BioAssay-Results Page: 87.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5310993#section=BioAssay-Results Page: 104.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5310993#section=BioAssay-Results Page: 87.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5310993#section=BioAssay-Results Page: 32.0

PubMed

Title	Date	PubMed
Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes.	2009-09	19567515
The second-meal phenomenon in type 2 diabetes.	2009-07	19366973
Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism.	2009-06	19276230
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.	2009-04	19336687
Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation?	2009-03	19246600
Diabetes treatment.	2009-03	19246581
Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.	2009-03	19106250
Extremely short duration high intensity interval training substantially improves insulin action in young healthy males.	2009-01-28	19175906
American College of Endocrinology Pre-Diabetes Consensus Conference: part three.	2008-12	19033421
Atrial natriuretic peptide induces postprandial lipid oxidation in humans.	2008-12	18835931
Butyrate ingestion improves hepatic glycogen storage in the re-fed rat.	2008-10-10	18847460
Changes in triglyceride levels over time and risk of type 2 diabetes in young men.	2008-10	18591400
Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus.	2008-09	18628354
Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals.	2008-09	18567819
Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.	2008-08	18553127
The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans.	2008-08	18505832
AAS, growth hormone, and insulin abuse: psychological and neuroendocrine effects.	2008-06	18827854
Glucose-insulin therapy, plasma substrate levels and cardiac recovery after cardiac ischemic events.	2008-04	18266096
Dose-response effects of free fatty acids on amino acid metabolism and ureagenesis.	2008-03	17973949
Inflammation and lipid accumulation in xanthoma disseminatum: Therapeutic considerations.	2008-02	18191707
Orlistat in the prevention of diabetes in the obese patient.	2008	18561508
Human visceral adipose tissue and the plasminogen activator inhibitor type 1.	2007-11	17471294
Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.	2007-08	17601993
Intense [18F]FDG tongue uptake in a case of acipimox-related angio-oedema during FDG-PET myocardial viability study.	2007-08	17546455
HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms.	2007-06-27	17597538
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.	2007-06	17299078
Dose-response effects of free fatty acids on glucose and lipid metabolism during somatostatin blockade of growth hormone and insulin in humans.	2007-05	17341555
Nicotinic acid receptor subtypes and their ligands.	2007-05	17238156
Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.	2007-04-11	17643322
Short-term manipulation of plasma free fatty acids does not change skeletal muscle concentrations of ceramide and glucosylceramide in lean and overweight subjects.	2007-04	17264178
Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration.	2007-03	17327445
Reduced plasma free fatty acid availability during exercise: effect on gene expression.	2007-03	17186295
Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics.	2007-03	17132823
Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.	2006-12	16803850
No low-fat diet for the failing heart?	2006-11-14	17101867
Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure.	2006-11-14	17088453
Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.	2006-11	16940448
Inhibition of lipolysis does not affect insulin sensitivity to glucose uptake in the mourning dove.	2006-07	16753324
Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.	2006-06	16931496
Free fatty acids decrease circulating ghrelin concentrations in humans.	2006-05	16645013
Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction.	2006-01	16391189
[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].	2006	17078215
Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.	2005-12	15998660
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.	2005-11	16249438
Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis.	2005-10	16189176
Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic patients.	2005-10	16096823
Inhibition of adipose tissue lipolysis increases intramuscular lipid and glycogen use in vivo in humans.	2005-09	15886227
[The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].	2005-05	16220793
The effects of exercise and adipose tissue lipolysis on plasma adiponectin concentration and adiponectin receptor expression in human skeletal muscle.	2005-03	15757860
Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox.	2005	16179286

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage is one 250 mg capsule 2 or 3 times daily to be taken with or after meals. The lower dose is advised in type IV and the higher dose in types IIA and IIB hyperlipoproteinaemias.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:58:35 GMT 2025` Edited by `admin` on `Mon Mar 31 17:58:35 GMT 2025`
Record UNII	K9AY9IR2SD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OLBETAM

Preferred Name

English

ACIPIMOX

Official Name

English

ACIPIMOX [MI]

Common Name

English

5-METHYLPYRAZINE-2-CARBOXYLIC ACID-4-OXIDE

Systematic Name

English

NSC-759818

Code

English

acipimox [INN]

Common Name

English

ACIPIMOX [MART.]

Common Name

English

Acipimox [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98151